Next Generation Platform for the Production of Biopharmaceuticals
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Biopharmaceutics".
Deadline for manuscript submissions: closed (31 May 2022) | Viewed by 2294
Special Issue Editor
Special Issue Information
Dear Colleagues,
The demand for biopharmaceuticals, such as therapeutic proteins, is increasing, and healthcare systems are facing tremendous costs to address unmet medical needs. Therefore, to meet the growing demand for biopharmaceuticals, the development of highly efficient production platforms is warranted. Although state-of-the-art industrial manufacturing processes allow productivity of over g/L for numerous monoclonal antibodies, the expansion of the biopharmaceutical industry pipeline with a wide range of non-native proteins, such as bispecific antibodies and fusion proteins, poses questions regarding both the manufacturability and timelines to achieve a commercially viable solution. This Special Issue aims to explore the emerging trends in the platforms and manufacturing processes for the production of biopharmaceuticals. In this Special Issue, original research articles and reviews are welcome. Research areas may include but not be limited to recent advances in mammalian-based production of biopharmaceuticals and manufacturing platforms, alternative mammalian expression platforms, including cell-free and gene-based expression systems, issues in manufacturing therapeutics in a non-native format, etc.
Dr. Jae Seong Lee
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- biopharmaceutical production using mammalian cells
- mammalian cell culture engineering
- alternative mammalian expression/manufacturing platform
- cell-free expression system for therapeutic protein production
- gene-based (DNA, RNA) biopharmaceutical production
- non-native difficult-to-express therapeutic protein
